Furamag capsules 50 mg. №30


Manufacturer: Latvia

urogenital infections: acute and chronic cystitis, pyelonephritis, urethritis, prostatitis; gynecological infections; for prophylactic purposes during urological operations, cystoscopy, and catheterization.



Furamag Composition

active substance Furamag: soluble furagin

1 capsule contains soluble furagin 50 mg

Furamag excipients: magnesium hydroxycarbonate, potassium carbonate, talc, titanium dioxide capsule (E 171), quinoline yellow dye (E 104), gelatin.


hard gelatin capsules No. 3 yellow. Capsule contents: orange-brown to reddish-brown powder. Particles of white, yellow, orange and orange-brown color are allowed.

Antimicrobial agents for systemic use. Nitrofuran derivatives. ATX code J01X E.



Furamag is a complex compound of soluble furagin and magnesium hydroxycarbonate in a ratio of 1: 1, which has fundamentally different pharmacological properties than simple furagin (after taking the drug furamag in the acidic environment of the stomach, the conversion of furagin, soluble into fugitive furagin, does not occur, therefore the bioavailability of Furamag is 3 times higher than regular furagin).

Furamag has a wide antibacterial spectrum of action against gram-positive and gram-negative microorganisms. Furamag is effective against gram-positive cocci (streptococci and staphylococci), gram-negative rods (escherichia circle, salmonella, shigella, proteus, klebsiella, enterobacteria), protozoa (lamblia). Furamag, in comparison with other nitrofurans, exhibits higher activity in staphylococci, Escherichia coli, Aerobacter aerogenes, Bact. Citrovorum, Proteus mirabilis, Proteus morganii. Furamag is also more effective for Enterococcus faecalis, Staphylococcus spp. compared with other groups of antimicrobial drugs.

Furamag Pharmacokinetics.

After taking Furamag capsules in the acidic environment of the stomach, the conversion of furagin soluble to furagin does not occur, due to which the bacteriostatic and bactericidal effect is significantly increased. After absorption in the digestive tract (mainly from the small intestine by passive diffusion), a bacteriostatic concentration of furamag is formed into the hepatic portal vein system.

The absorption of nitrofurans from the distal segment of the small intestine exceeds the absorption from the proximal and middle segment by 2 and 4 times, respectively. Nitrofurans are poorly absorbed in the colon.

Clinically important, the high content of the active substance in the lymph (delays the spread of infection through the lymphatic tract). In bile, the concentration of furamag is several times higher than in the blood serum, and in the cerebrospinal fluid it is several times lower than in the blood serum. In saliva, the content of soluble furagin is 30% of its concentration in the blood serum. The concentration of furagin, soluble in blood and tissues, is relatively low, which is associated with its rapid release, while the concentration in the urine is much higher than in the blood. The maximum concentration in the blood remains from 3 to 8:00, it is found in the urine 3-4 hours after taking the drug. The excretion of furagin soluble by the kidneys occurs by glomerular filtration and tubular secretion (85%), partially undergoes reverse reabsorption in the tubules, to a lesser extent, biotransformation is carried out (less than 10%), which occurs in the liver and kidneys. In the case of a decrease in renal excretory function, the metabolic rate increases. At low concentrations of furagin, soluble in urine, the process of filtration and secretion prevails, at high concentrations, secretion decreases and reabsorption increases.

Furamag Indications

Infections caused by soluble microorganisms sensitive to furagin: urogenital infections (acute and chronic cystitis, urethritis, pyelonephritis, prostatitis), gynecology